595610-50-7

Basic information

• Product Name: 5-(3-CHLOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLIC ACID
• Synonyms: 5-(3-CHLOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLIC ACID;5-(3-CHLOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLIC ACID, 95+%;5-(3-Chlorophenyl)-1H-pyrazole-3-carboxylic acid ,97%;3-(3-chlorophenyl)-1H-pyrazole-5-carboxylic acid;5-(3-chlorophenyl)-2H-pyrazole-3-carboxylic acid;MFCD09853449
• CAS NO: 595610-50-7
• Molecular Formula: C₁₀H₇ClN₂O₂
• Molecular Weight: 222.63
• Mol File: 595610-50-7.mol
• Article Data: 3

Chemical Properties

• Melting Point: 238-240℃
• Boiling Point: 520.879 °C at 760 mmHg
• Flash Point: 268.818 °C
• Appearance: /
• Density: 1.477 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.653
• Storage Temp.: 2-8°C
• PKA: 3.83±0.10(Predicted)
• CAS DataBase Reference: 5-(3-CHLOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-CHLOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLIC ACID(595610-50-7)
• EPA Substance Registry System: 5-(3-CHLOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLIC ACID(595610-50-7)

Safety Data

• Statements: 20/21/22
• Safety Statements: 7/8-36/37
• Hazardous Substances Data: 595610-50-7(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white powder

InChI:InChI=1/C10H7ClN2O2/c11-7-3-1-2-6(4-7)8-5-9(10(14)15)13-12-8/h1-5H,(H,12,13)(H,14,15)

Upstream product

• 1285545-03-0 ethyl 5-(3-chlorophenyl)-1H-pyrazole-3-carboxylate 
• 57961-48-5 ethyl 4-(3-chlorophenyl)-2,4-dioxobutanoate 
• 99-02-5 3'-Chloroacetophenone 

Relevant articles and documents

Pyrazole amide derivatives as well as preparation method and application thereof

The invention relates to pyrazole derivatives represented by a general formula I shown in the description, or a stereoisomer and tautomer of the pyrazole derivatives, a preparation method of the pyrazole derivatives, and an application of the of the pyraz

Pyrazole derivatives as partial agonists for the nicotinic acid receptor

Nicotinic acid as a hypolipidemic agent appears unique due to its potential to increase HDL cholesterol levels to a greater extent than other drugs. However, it has some side effects, among which severe skin flushing is the most frequent and often limits patients' compliance. In a search for novel agonists for the recently identified and cloned G protein-coupled nicotinic acid receptor, we synthesized a series of substituted pyrazole-3-carboxylic acids that proved to have substantial affinity for this receptor. The affinities were measured by inhibition of [3H] nicotinic acid binding to rat spleen membranes. Potencies and intrinsic activities relative to nicotinic acid were determined by their effects on [35S]GTPγS binding to rat adipocyte and spleen membranes. Interestingly, most compounds were partial agonists. In particular, 2-diazabicyclo-[3,3,O 4,8]octa-3,8-diene-3-carboxylic acid (4c) and 5-propylpyrazole-3-carboxylic acid (4f) proved active with Ki values of approximately 0.15 μM and EC50 values of approximately 6 μM, while their intrinsic activity was only ～50% when compared to nicotinic acid. Even slightly more active was 5-butylpyrazole-3-carboxylic acid (4g) with a Ki value of 0.072 μM, an EC50 value of 4.12 μM, and a relative intrinsic activity of 75%. Of the aralkyl derivatives, 4q (5-(3-chlorobenzyl)pyrazole-3-carboxylic acid) was the most active with a relatively low intrinsic activity of 39%. Partial agonism of the pyrazole derivatives was confirmed by inhibition of G protein activation in response to nicotinic acid by these compounds. The pyrazoles both inhibited the maximum effect elicited by 100 μM nicotinic acid and concentration dependently shifted nicotinic acid concentration-response curves to the right, pointing to a competive mechanism of action.